文献速递药物不良反应与药物警戒

拉贝洛尔致急性主动脉夹层患者高钾血症:罕见但临床相关的不良反应

Labetalol-induced hyperkalemia in acute aortic dissection: A rare but clinically relevant adverse effect.
PubMed 文献 · Am J Health Syst Pharm · 2026-10-12

本文报告一例59岁男性急性B型主动脉夹层患者,在口服拉贝洛尔滴定至600 mg用于抗冲动治疗期间出现持续性非溶血性高钾血症(5.2至5.8 mmol/L),与剂量递增时间相关,尽管肾功能保留且未使用RAAS抑制剂或肝素。停用拉贝洛尔并换用卡维地洛后48小时内血钾恢复正常,Naranjo评分7分提示很可能的不良反应。

要点

  • 拉贝洛尔可通过β-2受体阻滞诱发高钾血症,不依赖肾功能损害或典型诱因药物。
  • 急性主动脉综合征使用拉贝洛尔时应监测血钾。
  • 卡维地洛可能是对血钾平衡更安全的非选择性β受体阻滞剂替代选择。

核心结论

  • 拉贝洛尔可能独立于肾功能损害或典型诱发药物引起临床显著的高钾血症。

研究设计与样本

  • 单例病例报告,患者为59岁男性,有高血压、糖尿病、哮喘及多种物质使用障碍。

主要发现

  • 口服拉贝洛尔滴定至600 mg后出现持续性非溶血性高钾血症,血钾5.2至5.8 mmol/L,与剂量递增时间相关。
  • 肾功能保留(血清肌酐1.4至1.8 mg/dL),且未使用RAAS抑制剂或暴露于肝素。
  • 停用拉贝洛尔换用卡维地洛后48小时内血钾恢复正常,未再使用降钾药物。
  • Naranjo不良反应概率量表评分为7分,提示很可能的不良反应。

关键数值与推荐

  • Naranjo评分7分对应很可能的不良反应。
  • 高钾血症定义为血钾5.2至5.8 mmol/L(非溶血样本)。

临床怎么用

  • 接受拉贝洛尔治疗的急性主动脉综合征患者应监测血钾。
  • 出现高钾血症且无其他典型诱因时,应考虑拉贝洛尔相关可能。
  • 需非选择性β受体阻滞时,卡维地洛可作为对血钾影响较小的替代选择。

局限性

  • 单例病例报告,因果关系判断受限。
  • 不能排除其他未识别因素对血钾的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperkalemia is a potentially life-threatening electrolyte abnormality often associated with renin-angiotensin-aldosterone system (RAAS) inhibitors, renal dysfunction, or potassium-sparing agents. Non-selective beta-blockers, including labetalol, may also precipitate hyperkalemia through beta-2 (β-2)-adrenergic blockade, although this adverse effect is underrecognized, particularly in patients without underlying renal disease. CASE PRESENTATION: A 59-year-old man with hypertension, diabetes, asthma, and polysubstance use disorder presented with severe chest pain and hypertensive emergency (243/132 mmHg). Imaging revealed aortic dilatation and confirmed acute type B aortic dissection. After initial medical management with intravenous (IV) esmolol and nicardipine, oral labetalol was initiated and escalated to 600 mg for anti-impulse therapy. The patient developed persistent, non-hemolyzed hyperkalemia (5.2 to 5.8 mmol/L) temporally correlating with labetalol dose escalation, despite preserved renal function (serum creatinine 1.4 to 1.8 mg/dL) and absence of RAAS inhibitors or heparin exposure. Conservative management failed, and the patient underwent thoracic endovascular aortic repair (TEVAR) with thoracic branch endoprosthesis (TBE). Post-operatively, labetalol was discontinued and replaced with carvedilol. Serum potassium (K+) normalized within 48 hours and remained without further K+ lowering agents. Naranjo Adverse Drug Reaction Probability Scale assessment yielded a score of 7, indicating a probable adverse drug reaction. CONCLUSIONS: Labetalol may induce clinically significant hyperkalemia independent of renal impairment or typical precipitating medications. This case highlights the importance of monitoring K+ in patients receiving labetalol for acute aortic syndromes and supports carvedilol as a potentially safer non-selective beta-blocker alternative with respect to K+ homeostasis.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Butt F, Khan Z, Badua PM, et al. Labetalol-induced hyperkalemia in acute aortic dissection: A rare but clinically relevant adverse effect. Am J Health Syst Pharm. 2026. PMID: 42862110. doi:10.1093/ajhp/zxag297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。